NorthWest Biotherapeutics Inc (NWBO)

[Nemesis18]

I think that the Dendritic Cell approach when used as an adjuvant, or piggy back treatment has a real chance of making inroads into the treatment of GBM4 over the next 5-10 years.

Whether NWBO’s licensed Variant is the one to lead that vanguard remains to be seen shortly.
But if it should fall at this first significant Regulatory Hurdle, Advent is perfectly placed now to pick up the third party work that will fill the void left in this field.
In this regard, LP has selfishly covered her bases very well, and should be respected for that ruthless self-preservation business instinct !

Don’t blame the Player, blame the game.

In terms of DCVAX-L replacing Chemotherapy as the front line treatment, off the back of one liquidised P3 trial, there is zero chance of that happening.
But as other DC variants start coming through over the years, I think that this approach will certainly gain some Temozolomide etc ( which is a fecking brutal, scorched-earth treatment )